TRANSCRIPT

Q3 2024 — Earnings call remarks

Q3 2024PDF · 10 pages181 KB
1
Earnings Conference Call
Third Quarter 2024 Remarks
October 15, 2024
Moderator:
Good morning, and welcome to the UnitedHealth Group Third Quarter 2024 Earnings
Conference Call. A question-and-answer session will follow UnitedHealth Group’s prepared
remarks. As a reminder, this call is being recorded.
Here is some important introductory information. This call contains “forward-looking” statements
under U.S. federal securities laws. These statements are subject to risks and uncertainties that
could cause actual results to differ materially from historical experience or present expectations.
A description of some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements included in our
current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-GAAP to GAAP
amounts is available on the “Financial & Earnings Reports” section of the Company’s Investor
Relations page at www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued this morning
and in our Form 8-K dated October 15, 2024, which may be accessed from the Investor
Relations page of the Company’s website. I will now turn the conference over to the chief
executive officer of UnitedHealth Group, Andrew Witty.
Andrew Witty
Good morning and thank you for joining us.
As you saw in our release, the people of UnitedHealth Group continue to deliver on our
growth pillars. Our teams are providing more people with more high-quality health care
services and benefits, and restlessly looking for ways to simplify the health system and
deliver more value for patients, employers and providers alike.
By the end of this year, we will have grown to:
• 	Serve more than 2 million new consumers with commercial offerings.
• 	Fulfill more than 1.6 billion prescriptions through Optum Rx.
• 	And care for 4.7 million people in value-based arrangements.

-- 1 of 10 --

2
Our people will have done all this and more in a challenging period, navigating:
• 	The first year of the CMS Medicare rate cuts and its impact on member mix.
• 	The effects of the state-driven Medicaid member redeterminations.
• 	Certain novel care patterns.
• 	And the Change Healthcare cyberattack.
While many of those factors could not have been anticipated, thanks to our people’s
efforts, we can affirm a full year 2024 earnings outlook still within the range we first
offered back in November 2023. It is a distinctive part of the culture of UnitedHealth
Group that we continue to strive to deliver on our financial commitments to you through
changing environments and unforeseen challenges.
As we look to 2025, and I will address this shortly, we remain in a dynamic period for the
health care sector. Amid this, it’s important that we continue to invest in the durable
value-creating capabilities of this company that support our 13 to 16% long term growth
objective.
We will balance our commitments to investing in the promising future before us with
managing the known and potential challenges. We remain highly optimistic for the
future, even as we are respectful of the pressures the sector faces again next year.
Even within this environment, we are well-positioned to continue our growth in the years
ahead.
I want to highlight two important reasons for this optimism.
First is our relentless focus on execution, quality and innovation.
In particular, we continue to work tirelessly to improve people’s experiences with the
health system. To that end, this month we launched a first of its kind national Gold Card
program, which will reduce the number of prior authorizations by 500,000 every year for
qualified in-network providers. This can help improve both the quality and the
affordability of care, while reducing friction in the system.
Artificial Intelligence is starting to be an important tool in improving our work. Our
advanced practice clinicians use AI to summarize lengthy patient histories, freeing up

-- 2 of 10 --

3
hundreds of hours that can better be spent caring for people. Our nurses use generative
AI to review documentation more efficiently, saving time and improving patient service.
AI is helping our consumer advocates, powering tens of millions of consumer
interactions and provider searches. This allows our advocates to spend more time with
people on more complex inquiries, driving better efficiency while also improving the
consumer experience as reflected in higher NPS scores.
And finally, using AI to help build software is enabling technology engineering teams to
enhance the speed and quality necessary to help drive our technology modernization.
Our focus on execution and quality is also evident in the Medicare Advantage plans we
are offering for 2025. Once again, we focused on consumer value and, as much as
possible, on benefit stability – even as we navigated the adverse Medicare funding
environment. With annual enrollment beginning today, we believe we will continue to be
a top choice for consumers.
A second element underpinning our growth is delivery on our commitment to the
transition of the health system to value-based care.
For over 20 years, there has been a bipartisan consensus among health care experts
and policymakers that value-based care — that is, integrated, patient-centered and
outcome-focused care — is superior to the often fragmented and unnecessarily
expensive fee-for-service system.
Across four presidential administrations, CMS has called for private-public innovation in
the development of value-based care models in Medicare and Medicaid. It provides
better outcomes for patients. It saves money for the customers and taxpayers who fund
care. And it empowers clinicians to focus on providing the most beneficial care.
The rationale for this decades-long effort to develop value-based care is both simple
and sound:
• 	It moves from incentives based solely on volume to incentives based on a patient’s
health outcomes and experience.

-- 3 of 10 --

4
• 	And it helps ensure patient care is delivered not at the highest cost sites of service
… but rather those that combine the highest quality and value.
The effectiveness of value-based care for patients is proven and powerful … and it’s
good for the system.
At UnitedHealth Group, we are purposefully organized to support the transition to value-
based care.
It requires deep engagement with patients, setting the foundation to move to more
coordinated care:
• 	Connecting patients to primary care earlier.
• 	Driving clinically accurate diagnoses.
• 	More effectively recognizing and managing chronic conditions.
• 	And slowing disease progression.
We are seeing the benefits of this work come to fruition. People served by Optum
Health’s value-based care models are more likely to receive cancer screenings and be
in better control of their diabetes and hypertension than people in fee-for-service
Medicare … and 10% less likely to visit the emergency room or be re-admitted to a
hospital.
One example of the impact of better care coordination is our Emergency Room Safe
Discharge program, which helps patients who may be at risk for unnecessary and
expensive ER use and readmissions. We have learned that the specific ways in which a
discharge is managed can have a substantial impact on readmissions, which are a
problem for both patients and facilities.
Our nurse care managers proactively engage the emergency teams to provide them
relevant information from the outpatient medical record, and to facilitate a safe
discharge. This approach, currently in eight markets, is already helping to avoid
hundreds of inpatient stays each month. It preserves emergency resources for those
who truly need them, saves money and is a better experience for patients.

-- 4 of 10 --

5
Our many care offerings now serve people in value-based care arrangements in dozens
of service areas, integrating primary, surgical, behavioral and home care. These
patients come from many diverse payers and employers – a clear sign of confidence
from the market that we are on the right track.
This is the value proposition of UnitedHealth Group: committed to serving patients,
providers, payers and customers with quality, integrity and innovation; and joining with
federal and state governments in the effort to help build a better health system that
meets the needs of all stakeholders now and into the future.
Fundamentally, we continue to grow because more people and organizations are
purchasing more of the products and services we offer. It’s a simple statement to make,
yet a hard thing to do year in and year out. But it’s the enduring reason for our optimism
about the long-term growth and future of this enterprise.
Now, I’ll turn it over to John Rex, our president and chief financial officer.
John Rex
Thank you, Andrew.
Strong growth across the company sets us up well to deliver upon our commitments to
you. Amid all the puts and takes of this unusual year, we are seeing what we always
look for:
• 	New products and innovations taking root among customers.
• 	More people being served through our services.
• 	And continued improvement in the experience people have.
These are key to our long-term success.
I’ll start today by offering some observations on care activity patterns, as we know that
is most likely top of mind for many of you.

-- 5 of 10 --

6
Certain care patterns persisted at higher levels than we expected in the period for three
specific, and we believe, primarily transitory reasons … two of which we noted last
quarter.
First, the still pronounced upshift in coding intensity by hospitals, which we flagged last
quarter. In some cases, the coding actions are extreme. Certain entities have been
notably and persistently aggressive, having upshifted their coding intensity factors by
more than 20%. We are actively addressing this unnecessary additional cost burden to
the health system.
The second item, also noted last quarter, is the continued timing mismatch between the
current health status of Medicaid members and state rate updates. States often use
care activity data that is well over a year old in setting their rates. That typically has
minimal impact when member mix levels are relatively stable. Eligibility
redeterminations significantly shifted both the number and average acuity of people
covered has changed. As a result of the lagging care activity data, as well as the annual
rate cycle timing, updates remain well short of current care activity ... a factor that for us
was more pronounced through the period than anticipated.
A third item that emerged more substantially in the period was a rather rapid
acceleration in the prescribing of certain high-cost specialty medications, primarily those
used to treat cardiovascular disease, auto-immune disorders and cancer. We believe a
contributing factor to the acceleration was the Inflation Reduction Act, which eliminated
the individual coinsurance requirement during the catastrophic coverage phase. As
many of you know, more people enter this phase in the second half of the year.
While we anticipated this would become a more meaningful factor in 2025 … drug
manufacturer campaigns pulled some of this activity into this year more sharply than
anticipated.
With that, let’s turn to our third quarter results.
Revenues of $101 billion grew more than 9% over the prior year, with strong growth
again at both Optum and UnitedHealthcare.

-- 6 of 10 --

7
Optum Health revenues grew by over $2 billion and are approaching $26 billion. This
was driven by an increase in both the number and type of care services we offer and
the patients we serve, especially in the home and among those with complex needs.
Optum Rx revenues grew by over $5 billion to more than $34 billion, driven by strength
in our pharmacy care offerings, as well as growth in pharmacy benefits management
from new customers, and expanding specialty services.
Optum Insight revenues in the quarter were stable, approaching $5 billion, and the
nearly $33 billion revenue backlog increased by more than $1 billion from last year.
Turning to UnitedHealthcare:
Our domestic commercial business has added more than 2.4 million people through the
third quarter. Selling season indications are tracking favorably as we head into ’25,
reflecting continued strong uptake of UnitedHealthcare’s innovative offerings.
Our Medicare Advantage plans on offer this fall balance providing as much benefit
stability as possible for seniors, while contending with the CMS funding cuts, IRA
changes and expected care patterns. The initial Stars ratings for plan year ’26 for
consumers in 4 star or better rated plans is largely consistent with what we saw in our
initial results last year. As has been the case in recent years, we expect these
percentages to increase.
In Medicaid, our new state customer, expansion and retention performance remains
strong, including recent awards in Massachusetts, Colorado, Rhode Island, Florida and
Michigan. We hope to continue to support people and families in the post-
redeterminations period and are advocating with states to ensure adequate funding and
resources for these often underserved people.
Our capital capacities remain strong and continue to underpin our long-term growth
objectives. In the quarter, cash flows from operations were $14 billion, or 2.2 times net
income and year-to-date, were nearly $22 billion. So far this year, we have returned
$9.6 billion to shareholders via dividends and share repurchase. Additionally, we have
invested more than $11 billion in a wide range of strategic opportunities, including

-- 7 of 10 --

8
updating and extending our longstanding and productive relationship with AARP, to
better serve older Americans.
As highlighted last quarter, after the cyberattack we prioritized devoting resources to
support care providers over some activities such as share repurchase. Payments and
claims flows for most care providers have normalized and repayment of these capital
advances is underway.
Regarding Change Healthcare, for full year ’24, we now estimate the business
disruption costs will be about 75 cents per share, an increase of 10 cents from the
former mid-point. As you may recall, business disruption largely encompasses the loss
of revenues, combined with the costs of keeping these capabilities fully ready to serve.
These effects are not excluded from adjusted earnings.
We continue to work with customers to bring transaction volumes back to pre-event
levels and to win new business with our now more modern, secure and capable
offerings. We expect to continue to build back the business to pre-attack levels over the
course of ’25 and estimate next year’s full year impact will be roughly half of the ’24
level.
As we enter the final quarter of the year, we are narrowing our ’24 adjusted earnings
outlook to a range of $27.50 to $27.75, to reflect business disruption impacts and the
care patterns we discussed.
Our company’s ability to deliver within the range of the commitments established nearly
a year ago – even in challenging circumstances – is another example of the discipline
and innovation of the enterprise and the confidence we have in delivering diverse
growth for the long-term.
Now I’ll turn it back to Andrew.
Andrew Witty
Thanks, John.

-- 8 of 10 --

9
Before we turn to your questions, I want to provide some preliminary observations about
next year, which we will review in more depth at our upcoming investor conference.
Perhaps the most important element is that our businesses are operating well and our
growth potential remains strong. We see continued momentum in the selling season
performance for UnitedHealthcare’s commercial business and Optum Rx, which both
offer best in class innovation and performance for customers.
The consumer value-proposition of Medicare Advantage continues to be highly
compelling, and we see strong growth potential in this market for many years to come.
The Optum Health value-based care businesses that we have been building for well
over a decade are beginning to approach the very early stages of their potential … and
will be a key differentiating growth factor in the years ahead.
At the same time, and as we build for the future and contemplate our 2025 outlook, we
are taking into account several unique dynamics:
• 	First: The concurrent timing of the second year of the CMS Medicare rate cuts and
the most significant Inflation Reduction Act impacts into a single year … and the
negative effects of that on the people we serve.
• 	Second: Within Medicaid, the timing mismatch of state customer rate actions, which
do not yet reflect the higher acuity of remaining consumers.
• 	And third: A respectful view of the care activity that John noted. We are actively
addressing and managing for these … and continuing to believe our 2025 planning
assumptions appropriately capture these components, though we will be prudent in
an initial early view.
The majority of those 2025 factors are expected to be most impactful to the
UnitedHealthcare businesses.

-- 9 of 10 --

10
As a result, we anticipate stepping out for 2025 more conservatively than is typical. At
this distance we expect the upper end of the likely range we’ll offer in December as
being around $30 per share.
As always, we will seek to advance beyond this initial view as the year progresses, and
we remain committed to and focused on our long-term, 13 to 16% earnings per share
growth objective. We see 2025 as a year of opportunity in building to that commitment
… so you will see us investing in our growth pillars…aggressively modernizing our
company with AI and other technologies … and – always – exercising discipline in our
operating performance.
We look forward to discussing this with you in much greater detail at our Investor
Conference on December the 4th in New York.

-- 10 of 10 --